# CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

> **NCT02742727** · PHASE1,PHASE2 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- T-cell Prolymphocytic Leukemia
- T-cell Large Granular Lymphocytic Leukemia
- Peripheral T-cell Lymphoma, NOS
- Angioimmunoblastic T-cell Lymphoma
- Extranodal NK/T-cell Lymphoma, Nasal Type
- Enteropathy-type Intestinal T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD7 CAR-pNK cells

## Key facts

- **NCT ID:** NCT02742727
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2017-03
- **Final completion:** 2018-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2016-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02742727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02742727, "CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02742727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*